We searched MEDLINE, Current Contents, and PubMed with the terms “endometrial cancer”, “hysterectomy”, “lymphadenectomy”, “sentinel node”, “chemotherapy”, “radiation therapy”, “targeted therapy”, “fertility sparing management”, “ovarian preservation”, and “molecular classification” for articles published in English between Jan 1, 1990, and Jan 1, 2015. We also reviewed the reference lists of articles identified by this search. We focused our search strategy on systematic reviews, meta-analyses,
SeminarEndometrial cancer
Introduction
Endometrial cancer—a tumour originating in the endometrium—is the most common gynaecological tumour in developed countries, and its prevalence is increasing.1 As the disease is frequently symptomatic at an early stage, endometrial cancer is often diagnosed at stage I. Historically, standard treatment consisted of hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymph node dissection followed by adjuvant therapy tailored on the basis of final histology.
Management of endometrial cancer has become more complex during the past 5–10 years for several reasons: changes in histological classification that affect surgical management, adjuvant therapies, and prognosis; changes in the indications and modalities of lymphadenectomy; de-escalation of adjuvant therapy based on data from randomised trials; and discrepancies between the various classifications used to characterise recurrence risk factors.
These modifications have led national scientific societies to review the emerging data and unanswered questions, and to publish specific recommendations for endometrial cancer.2, 3, 4
This Seminar focuses on the epidemiology and the histological and molecular classification of endometrial cancer. We also describe current practice and trials of surgery, adjuvant treatment, and novel targeted therapies.
Section snippets
Epidemiology and risk factors
In 2012, around 320 000 new cases of endometrial cancer were diagnosed worldwide. Endometrial cancer is the fifth most common cancer in women (4·8% of cancers in women), who have a cumulative risk of 1% of developing the disease by age 75 years.1 It is the 14th cancer in terms of mortality (76 000 deaths); cumulative risk of death by age 75 years is 0·2%.1 The highest incidences in 2012 are estimated in the USA and Canada (19·1/100 000) and northern (12·9/100 000) and western Europe
Pathogenesis and histological or molecular classifications
In the past 30 years, endometrial cancer has been broadly classified into two subtypes on the basis of histological characteristics, hormone receptor expression, and grade (table 1).23 The most common subtype is low-grade, endometrioid, diploid, hormone-receptor-positive endometrial cancer, which has a good prognosis. Type II endometrial cancers are described as non-endometrioid, high grade, aneuploid, TP53-mutated, hormone-receptor-negative tumours that are associated with a higher risk of
Clinical presentation and diagnostic assessment
Abnormal uterine bleeding—sometimes associated with vaginal discharge and pyometra—is the most frequent symptom of endometrial cancer and is noted in about 90% of patients (usually during menopause). Patients with advanced disease might have symptoms similar to those of advanced ovarian cancer, such as abdominal or pelvic pain and abdominal distension. Disease can easily be diagnosed on the basis of office-based pipelle sampling or other techniques.34, 35 The histological information provided
Survival
Estimated cumulative risk of endometrial cancer is 0·96%; the corresponding mortality risk is 0·23% and mortality-to-incidence ratio is 0·24—lower than that of breast cancer (0·32), ovarian cancer (0·63), and uterine cervical cancer (0·55).1, 62 Most endometrial cancers (75%) are diagnosed at an early stage (FIGO stages I or II): 5 year overall survival ranges from 74% to 91%;5, 63 for FIGO stage III, 5 year overall survival is 57–66%, and for FIGO stage IV disease is 20–26%.5, 63 5 year
Principles of surgical treatment
Total hysterectomy and removal of both tubes and ovaries is the standard treatment for apparent stage I endometrial cancer and is effective in most cases. Alternatives to primary hysterectomy in women who want to preserve their fertility have been comprehensively reviewed.71 Hysterectomy and adnexectomy can be done with minimally invasive techniques (laparoscopy or robot-assisted surgery), vaginally, or laparotomically. The safety of laparoscopy has been shown in randomised clinical trials72, 73
Radiotherapy
Around 55% of patients with endometrial cancer have uterine-confined disease with low-risk features, and are treated with surgery only, which is associated with a 95% probability of relapse-free survival at 5 years (appendix).72, 76, 77 Four randomised trials and a Cochrane meta-analysis have assessed the role of external-beam pelvic radiation therapy (EBRT) in stage I endometrial cancer (appendix).55, 56, 98, 99, 100, 101, 102, 103, 104 In a Norwegian trial, 540 patients with clinical stage I
Management of metastatic or recurrent disease
Surgery or other local treatment (radiation therapy in a non-irradiated area) are options in patients with metastatic or recurrent disease—mainly in patients with an isolated centropelvic recurrence or a single metastatic site.115 5 year overall survival after exenteration for pelvic recurrence ranges from 20% to 40%.115, 116 Results of studies suggest that management of endometrial cancer with peritoneal spread could be similar to that of ovarian cancer, which emphasises the importance of
Targeted therapies
No approved targeted therapies are available for endometrial cancer. The PI3K/AKT/mammalian target of the rapamycin (mTOR) pathway is the most commonly deregulated pathway in endometrial cancer but results of trials with mTOR inhibitors showed response rates of less than 10% (table 5).125, 126, 127, 128, 129, 130, 131, 132 Several hypotheses have been put forward to explain the ineffectiveness of mTOR inhibitors in endometrial cancer: first, a preponderant cytostatic effect; second, limited
Genetic counselling
5–25% of endometrial cancers are related to high-risk germline mutations, which are characterised by early onset of disease—ie, before age 40 years.146 Genetic testing and counselling should be considered for women with endometrial cancer who are younger than 50 years, and those with a clinically significant family history of endometrial or colorectal cancer.147
Women with Lynch syndrome or hereditary non-polyposis colon cancer are at increased risk of endometrial, colon, and ovarian cancer
Screening
In the general population, evidence to support screening for endometrial cancer is insufficient. However, women—particularly those who are overweight—should be informed by their family doctor about the risks of endometrial cancer, and encouraged to consult their physician immediately in cases of uterine bleeding or spotting during the perimenopausal period.
No screening strategy has proven efficacy for women with hereditary non-polyposis colon cancer or Lynch syndrome. In view of the frequency
Management of comorbidities
Patients with comorbidities are more likely to be suboptimally managed, particularly in terms of lymph node dissection and adjuvant therapy. In a review of 12 studies,154 obesity did not seem to affect either progression-free or disease-specific survival. However, Arem and colleagues155 reported that patients with poorly differentiated endometrial cancer had a specific mortality hazard ratio of 1·39 (95% CI 1·04–1·85) per five-unit increase in BMI, whereas no differences were detected for well
Controversies and outstanding research questions
Recently completed and ongoing trials are focusing on the role of chemotherapy, radiation therapy, or a combination of both in patients with high-risk and advanced endometrial cancer (appendix). In the international PORTEC 3 trial, patients with high-risk endometrial cancer have been randomly assigned to EBRT alone or to a combination of EBRT and chemotherapy. In the GOG-258 trial, adjuvant chemotherapy alone is being compared with chemotherapy combined with radiotherapy (schedule as used in
Search strategy and selection criteria
References (158)
- et al.
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012
Int J Cancer
(2015) - et al.
Clinical practice guidelines for the management of patients with endometrial cancer in France: recommendations of the Institut National du Cancer and the Société Française d'Oncologie Gynécologique
Int J Gynecol Cancer
(2011) - et al.
Endometrial cancer: a review and current management strategies: part I
Gynecol Oncol
(2014) - et al.
Endometrial cancer: a review and current management strategies: part II
Gynecol Oncol
(2014) - et al.
Cancer statistics, 2015
CA Cancer J Clin
(2015) - et al.
Profile of women 45 years of age and younger with endometrial cancer
Obstet Gynecol
(1998) - et al.
Feasibility of ovarian preservation in patients with early stage endometrial carcinoma
Gynecol Oncol
(2007) - et al.
Endometrial cancer in women 40 years old or younger
Gynecol Oncol
(2001) - et al.
Incidence rates of endometrial hyperplasia, endometrial cancer and hysterectomy from 1980 to 2003 within a large prepaid health plan
Int J Cancer
(2012) - et al.
USA endometrial cancer projections to 2030: should we be concerned?
Future Oncol
(2014)
Metabolic syndrome and risk of endometrial cancer in the United States: a study in the SEER-medicare linked database
Cancer Epidemiol Biomarkers Prev
The dose-effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk
Br J Cancer
Estrogen–progestin replacement therapy and endometrial cancer
J Natl Cancer Inst
Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review
Cancer Epidemiol Biomarkers Prev
Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies
Lancet
Hormone replacement therapy and endometrial cancer risk: a meta-analysis
Obstet Gynecol
Epidemiology of endometrial cancer
Best Pract Res Clin Obstet Gynaecol
Diabetes mellitus and risk of endometrial cancer: a meta-analysis
Diabetologia
Lifestyle and endometrial cancer risk: a cohort study from the Swedish Twin Registry
Int J Cancer
Diabetes and endometrial cancer in the Iowa women's health study
Cancer Epidemiol Biomarkers Prev
Association between diabetes, diabetes treatment and risk of developing endometrial cancer
Br J Cancer
Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland
Obstet Gynecol
Two pathogenetic types of endometrial carcinoma
Gynecol Oncol
Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial
Gynecol Oncol
Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study
Virchows Arch
Integrated genomic characterization of endometrial carcinoma
Nature
FGFR2 as a molecular target in endometrial cancer
Future Oncol
Molecular characterization of undifferentiated carcinoma associated with endometrioid carcinoma
Am J Surg Pathol
The clinicopathologic significance of the loss of BAF250a (ARID1A) expression in endometrial carcinoma
Int J Gynecol Cancer
The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium
Mod Pathol
Immunohistochemical characterization of prototypical endometrial clear cell carcinoma—diagnostic utility of HNF-1β and oestrogen receptor
Histopathology
Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations
Mod Pathol
Utility of immunohistochemistry in predicting microsatellite instability in endometrial carcinoma
Am J Surg Pathol
My approach to the interpretation of endometrial biopsies and curettings
J Clin Pathol
The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis
Cancer
Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study
Cancer
Factors predictive of endometrial carcinoma in patients with atypical endometrial hyperplasia on preoperative histology
Anticancer Res
Prospective comparison of biopsy results from curettage and hysteroscopy in postmenopausal uterine bleeding
J Obstet Gynaecol Res
Effect of hysteroscopy on the peritoneal dissemination of endometrial cancer cells: a meta-analysis
Fertil Steril
Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis
Obstet Gynecol
Preoperative local staging of endometrial cancer: transvaginal sonography vs magnetic resonance imaging
Ultrasound Obstet Gynecol
Preoperative assessment of myometrial and cervical invasion in endometrial carcinoma by transvaginal ultrasound
Gynecol Oncol
Three-dimensional ultrasound with volume contrast imaging for preoperative assessment of myometrial invasion and cervical involvement in women with endometrial cancer
Ultrasound Obstet Gynecol
MR diffusion imaging for preoperative staging of myometrial invasion in patients with endometrial cancer: a systematic review and meta-analysis
Eur Radiol
Myometrial invasion in endometrial cancer: diagnostic accuracy of diffusion-weighted 3·0-T MR imaging—initial experience
Radiology
Endometrial cancer: preoperative staging using three-dimensional T2-weighted turbo spin-echo and diffusion-weighted MR imaging at 3·0 T: a prospective comparative study
Eur Radiol
A systematic review of tests for lymph node status in primary endometrial cancer
BMC Womens Health
Metabolic tumor volume by 18F-FDG PET/CT is prognostic for stage IVB endometrial carcinoma
Gynecol Oncol
Molecular imaging in the management of gynecologic malignancies
Gynecol Oncol
Potential role of multislice SPECT/CT in impingement syndrome and soft-tissue pathology of the ankle and foot
Nucl Med Commun
Cited by (1237)
Role of artificial intelligence in digital pathology for gynecological cancers
2024, Computational and Structural Biotechnology JournalMolecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer
2024, Cancer Treatment ReviewsCorrelation between estrogen receptor and programmed death ligand-1 in type I endometrial cancer
2024, European Journal of Obstetrics and Gynecology and Reproductive Biology: X